NYU Grossman School of Medicine

09/09/2026

Can we dial down the DNA mutations that naturally accumulate with age?

A new NYU Langone Health study in Cell Press offers an intriguing clue.

Researchers found that mice eating 30 percent fewer calories accumulated fewer naturally occurring DNA mutations across multiple tissues, including the liver and kidney. It’s the first time the effect has been demonstrated across a large fraction of the genome—not just in individual genes.

The pattern was especially striking in the quieter, less active stretches of DNA, offering a possible clue to how calorie restriction affects mutation buildup.

But this isn’t a case for extreme dieting. The mice were calorie-restricted for much of their lives, an approach that would be difficult to sustain—and potentially harmful—in people.

The more interesting implication is biological: the processes that influence how quickly mutations accumulate may not be entirely fixed.

First author Marta Grońska-Pęski, PhD, a postdoctoral fellow at NYU Grossman School of Medicine, and corresponding author Gilad D. Evrony, MD, PhD, an investigator in NYU Langone’s Center for Human Genetics and Genomics and the Jacob D. Goldfield Associate Professor of Pediatrics and Neuroscience at NYU Grossman School of Medicine, led the work with collaborators at University Hospitals Cleveland, the University of Texas Southwestern Medical Center, and the National Institutes of Health.

If researchers can identify the mechanisms—the biological levers that influence mutation rates—it may eventually be possible to slow mutation buildup in safer, more practical ways without dramatically cutting calories.

Gilad D. Evrony, MD, PhD, discusses what his team found—and where the science goes next.

Watch the full video or read more ➡️ https://bit.ly/4cxrVm7

09/07/2026

Recurrent patellar instability can be especially challenging when the underlying problem is severe trochlear dysplasia, in which an abnormal, shallow, or convex trochlea can contribute to recurrent instability.

For patients with significant bony abnormalities, soft tissue procedures alone may not be enough to address instability. In this case, orthopedic surgeons at NYU Langone Health used a combined approach with groove-deepening trochleoplasty, MQTFL reconstruction, and lateral lengthening to reshape the trochlear groove and improve patellar tracking.

After an early postoperative complication requiring manipulation under anesthesia, the patient ultimately regained full, painless motion and returned to regular activities in 6 months. At approximately 2.5 years, she continued to do the activities she wanted, including biking, with no recurrent instability and minimal discomfort.

The case demonstrates how individualized surgical planning can help young, active patients with complex patellofemoral instability achieve durable functional improvement.

Read more ⤵️

NYU Langone Orthopedics’ Drs. Guillem Gonzalez-Lomas and Laith Jazrawi discuss groove-deepening trochleoplasty with MQTFL reconstruction and lateral lengthening for a young, active patient with high-grade trochlear dysplasia, highlighting outcomes after three years. Learn more.

09/02/2026

A new study led by NYU Grossman School of Medicine researchers and published in JAMA Pediatrics, found no association between low-level pesticide exposure and autism-related social traits in children.

The findings do not mean these pesticides are safe or rule out potential risks at higher levels of exposure. More long-term research is needed to understand how environmental and genetic factors may contribute to autism.

Read the more about the study ⤵️

NYU Langone researchers find no link between exposure to organophosphate pesticides during pregnancy and social difficulties seen in autism. Learn more.

08/31/2026

Treating gastric and intestinal obstructions can be complex, and many patients need more precise, less invasive options.

At NYU Langone Health, gastroenterologists Jessica Widmer, DO, and Galen Leung, MD, are among the first experts in the United States to use a newer form of endoscopic ultrasound-guided gastroenterostomy, or EUS-GE.

Using an exchangeable double-balloon catheter, the technique creates a more stable target for stent placement, helping bypass the obstruction and allowing food, liquids, and air to move through the GI tract. Benign indications will likely expand quickly beyond typical anatomy to address obstructions involving alternate postsurgical anatomy.

For patients, this approach may mean less postoperative pain, a faster return to eating, and a shorter hospital stay.

Read more ⤵️

NYU Langone Health’s Dr. Jessica Widmer and Dr. Galen Leung discuss how a promising new approach expands options for malignant and benign gastrointestinal obstructions. Learn more.

08/28/2026

Using cannabis in multiple forms may be a warning sign of heavier use and possible addiction, especially in younger adults, according to our new research.

In a nationally representative study published in Addictive Behaviors, our researchers found that about 14% of cannabis users belonged to a “polymodal” group, using nearly every form of cannabis, including smoking, va**ng, edibles, and dabbing.

About half of this group used cannabis daily, and approximately 67% met criteria for cannabis use disorder, the highest rate among the groups studied.

The findings highlight why it’s important to ask not only whether someone uses cannabis, but how they use it. This may help identify when additional assessment or counseling about potential risks is needed.

Read more: https://bit.ly/4hP00BB

08/26/2026

Dr. Eric J. Strauss reflects on 16 years of shaping orthopedic surgical education at NYU Langone Health and how the nation’s largest orthopedic surgery residency program is preparing the next generation of surgeons.

“Despite our size, we’ve worked hard to preserve a close-knit environment.”

Under his leadership, the program emphasizes broad clinical exposure, early operative experience, individualized mentorship, and training that continues to evolve alongside advances in technology and patient care.

Dr. Strauss also highlights the importance of collaboration, mentorship, and a strong culture in developing future leaders in orthopedic surgery.

Read the full Q+A ⤵️

Dr. Eric Strauss discusses what distinguishes NYU Langone’s orthopedic residency—the nation’s largest—and how it prepares future leaders. Learn more.

08/25/2026

A multidisciplinary team at NYU Grossman School of Medicine has received a $19.67 million, seven-year funded award from the Patient-Centered Outcomes Research Institute - PCORI to lead a large multicenter clinical trial examining whether low-dose ketamine can improve pain control and recovery after surgery for serious orthopedic injuries.

The Ketamine for Pain after Orthopedic Surgery for Trauma (K-POST) trial is expected to enroll 1,800 patients across multiple clinical sites. The study will compare standard pain treatment with standard treatment plus a low-dose ketamine infusion during and after surgery, examining both immediate pain control and longer-term recovery.

The study is NYU Grossman School of Medicine’s first award through PCORI’s Phased Large Awards for Comparative Effectiveness Research (PLACER) program, which supports large-scale comparative-effectiveness research designed to inform real-world care.

The multidisciplinary K-POST team brings together expertise in pain medicine, orthopedic surgery, population health, biostatistics, and anesthesiology.

Read more about the study ⤵️

We use cookies and similar tools to give you the best website experience. By using our site, you accept our Websites Privacy Policy.

08/24/2026

Muscle-invasive bladder cancer with variant features can be aggressive and has historically required intensive treatment, including chemotherapy and complete bladder removal.

In this case, NYU Langone Health physicians highlight how response to systemic therapy can help guide a more individualized surgical plan. After multidisciplinary reassessment, a bladder-preserving approach offered both strong cancer control and meaningful functional benefits.

Final pathology showed no remaining cancer, while the patient maintained bladder function and reported improved quality of life.

The case shows that select patients who respond strongly to chemotherapy may achieve cancer control while preserving bladder function through multidisciplinary care.

Read the full case ⤵️

NYU Langone urologist Dr. Katie Murray discusses how an excellent response to chemotherapy enabled bladder preservation for a man in his late 80s with variant muscle-invasive bladder cancer (MIBC). Learn more.

08/21/2026

Advancing a new frontier in pancreatic cancer treatment.

Shohei Koide, PhD, inaugural director of Cancer Biologics at Perlmutter Cancer Center at NYU Langone and professor of biochemistry and molecular pharmacology at NYU Grossman School of Medicine, has been selected as a 2026 Stephenson Global Scholar Grant recipient.

Dr. Koide is one of eight investigators worldwide selected for the $6.7 million grant program supporting innovative research to change the future of pancreatic cancer care.

His research will focus on developing antibodies that target LCN2, a protein that helps pancreatic tumors keep cancer-fighting immune cells from reaching them. By targeting this pathway, Dr. Koide’s team aims to develop new strategies that help the immune system better recognize and attack pancreatic tumors.

A pioneer in engineered binding proteins, Dr. Koide developed the widely adopted Monobody platform, which enables researchers to design proteins that precisely recognize disease targets. His work continues to advance new approaches for understanding and treating cancer.

Through bold science and innovation, NYU Langone researchers are working to uncover new possibilities for patients with pancreatic cancer. Read more ➡️ https://bit.ly/4bN1mZV

08/21/2026

A personalized mRNA vaccine from Moderna and Merck showed promising results in a Phase 3 trial involving people with high-risk melanoma.

When combined with Keytruda, the vaccine appeared to delay cancer recurrence. NYU Langone Health’s Janice Mehnert, MD, senior investigator of an earlier trial of the vaccine, called the results exciting and a promising development for cancer research.

Read more about the findings and what they could mean for the future of personalized cancer treatment. ⤵️

The companies haven’t published the trial data, but they said the experimental treatment extended the time before cancer returned in high-risk patients.